Viatris Inc

VTRSNASDAQ · USD
17.27USD+0.32 (+1.86%)
969

Viatris Inc (VTRS) Covered Calls

As of September 18, 2026, VTRS has 22 covered call opportunities in the coming three months. Return ranges from 2.7 to 51.0% until expiration. Annualized return ranges from 3.9 to 106.0%. The nearest expiration is October 16, 2026. Maximum potential profit is $865.

Read more

Running VTRS covered calls helps you generate consistent income from Viatris Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Viatris Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best VTRS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if VTRS stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling VTRS covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Viatris Inc covered call is worth writing.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.

It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Income-focused investors, long-term VTRS holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling VTRS covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Viatris Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV percentile62.70% Neutral
  • Market cap (M$)19,469
  • 52 weeks high-7.83%
  • 52 weeks low79.75%
  • Analyst recommendationBuy
    2.33
  • Target price$19.00
    9.35% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-05
  • P/E
  • Future P/E6.36
  • EPS (ttm)-0.36
  • EPS growth next 5 years6.96%

As of September 18, 2026

2026-11-206320.0017.990.050.25310.0018.29105.96-0.29+0.1410.20
2027-01-1511922.0029.790.050.35510.0030.0992.29-0.29+0.135850.30
2026-10-162818.006.190.100.25115.006.7888.44-0.59+0.242,0590.15
2027-01-1511921.0023.890.050.30410.0024.1974.19-0.29+0.131400.25
2026-11-206319.0012.090.050.55210.0012.3971.78-0.29+0.2400.50
2027-01-1511920.0017.990.250.45330.0019.4759.72-1.47+0.222,8040.20
2026-11-206318.006.190.200.85125.007.3742.73-1.18+0.37150.65
2027-01-1511919.0012.090.150.75220.0012.9839.81-0.88+0.292,7640.60
2028-01-2149025.0047.490.601.25865.0051.0338.01-3.54+0.272190.65
2027-04-1621020.0017.990.500.85355.0020.9436.40-2.95+0.3120.35

As of September 18, 2026

Sell covered calls with the data behind you

Find the best VTRS covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial